Zoetis ZTS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| International | $4.4B+7.7% | $4.23B+3.1% | $4.15B+2.6% | $4.12B+3.4% | $4.08B+3.6% | |
| U.S. | $5B-1.8% | $5.1B+0.5% | $5.12B+1.8% | $5.14B+5.9% | $5.09B+8.1% | |
| Gross Profit by Business | ||||||
| International | $3.05B+9.5% | $2.93B+4.9% | $2.87B+4.6% | $2.85B+5.6% | $2.79B+3.8% | |
| U.S. | $4.17B-0.2% | $4.26B+2.8% | $4.26B+4.8% | $4.25B+8.3% | $4.18B+9.9% | |
| Nonoperating Income (Expense) by Business | ||||||
| International | $1M0.0% | $2M+100% | $1M-50.0% | $1M-50.0% | $1M-66.7% | |
| U.S. | $0+100% | $0+100% | -$3M-150% | -$3M-150% | -$3M-150% | |
| Operating expenses by Business | ||||||
| International | $698M+3.4% | $686M+2.2% | $683M+4.1% | $673M+2.7% | $675M+4.5% | |
| U.S. | $811M-1.1% | $817M+1.5% | $836M+7.6% | $834M+6.9% | $820M+4.1% | |
| Income before provision for taxes on income by Business | ||||||
| International | $2.35B+11.5% | $2.24B+5.8% | $2.19B+4.8% | $2.18B+6.6% | $2.11B+3.6% | |
| Other business activities | -$574M-2.0% | -$566M-0.7% | -$558M-0.9% | -$555M-2.8% | -$563M-9.5% | |
| U.S. | $3.36B-0.1% | $3.44B+3.1% | $3.43B+4.4% | $3.42B+8.9% | $3.36B+11.8% | |
| Depreciation and amortization expense by Business | ||||||
| International | $103M+7.3% | $100M+4.2% | $97M-1.0% | $96M-1.0% | $96M+2.1% | |
| Other business activities | $53M+17.8% | $51M+18.6% | $52M+36.8% | $47M+23.7% | $45M+32.4% | |
| U.S. | $93M+10.7% | $93M+9.4% | $90M+3.4% | $85M-1.2% | $84M-1.2% | |
| Cost of Sales by Business | ||||||
| International | $1.34B+3.9% | $1.31B-0.5% | $1.28B-1.7% | $1.27B-1.3% | $1.29B+3.0% | |
| U.S. | $837M-8.8% | $842M-10.0% | $858M-10.8% | $894M-4.1% | $918M+0.4% | |
| Revenue by Product | ||||||
| Animal health diagnostics | $448M+9.8% | $435M+12.7% | $424M+12.2% | $415M+11.6% | $408M+11.8% | |
| Anti-infectives | $1.03B-2.7% | $1.03B-6.8% | $1.02B-5.4% | $1.01B-5.4% | $1.06B+0.7% | |
| Cattle | $1.53B+3.0% | $1.48B-3.7% | $1.46B-4.8% | $1.45B-4.3% | $1.48B-0.9% | |
| Contract manufacturing & human health | $110M+22.2% | $117M+46.3% | $108M+37.6% | $106M+37.7% | $90M+14.6% | |
| Dermatology | $1.71B+2.5% | $1.74B+5.3% | $1.74B+7.6% | $1.72B+10.2% | $1.67B+11.5% | |
| Fish | $299M+18.7% | $288M+19.0% | $272M+13.8% | $264M+16.8% | $252M+16.7% | |
| Horses | $6.29B+5.1% | $6.28B+4.8% | $6B+13.6% | $6B+13.4% | $5.99B+13.4% | |
| Other Non Pharmaceuticals | $263M0.0% | $268M+5.9% | $263M+5.6% | $261M+5.2% | $263M+6.5% | |
| Other pharmaceutical | $696M+5.5% | $696M+5.8% | $688M+7.2% | $679M+6.3% | $660M+0.6% | |
| Pain and sedation | $833M-3.6% | $837M-1.6% | $845M+2.1% | $860M+13.8% | $864M+27.1% | |
| Parasiticides | $2.37B+6.5% | $2.35B+9.2% | $2.33B+10.0% | $2.29B+11.8% | $2.22B+10.0% | |
| Poultry | $444M-10.1% | $432M-18.0% | $432M-19.6% | $465M-11.4% | $494M-5.7% | |
| Sheep and other | $92M+9.5% | $91M+11.0% | $90M+11.1% | $86M+3.6% | $84M-5.6% | |
| Swine | $478M-3.2% | $460M-10.9% | $463M-12.1% | $483M-8.0% | $494M-6.4% | |
| Vaccines | $2.03B+12.0% | $1.95B+6.8% | $1.9B+4.0% | $1.87B+3.5% | $1.81B+1.1% | |
| Revenue by Geography | ||||||
| Australia | $343M+5.5% | $333M+4.4% | $329M+4.8% | $325M+3.2% | $325M+3.5% | |
| Brazil | $395M+0.3% | $386M-6.8% | $387M-7.4% | $388M-7.2% | $394M-3.9% | |
| Canada | $296M+3.5% | $293M+5.8% | $288M+5.1% | $284M+4.8% | $286M+7.5% | |
| Chile | $143M+12.6% | $140M+13.8% | $130M+4.8% | $132M+6.5% | $127M-3.8% | |
| China | $230M-7.6% | $222M-17.8% | $237M-12.2% | $253M-9.0% | $249M-15.3% | |
| France | $162M+5.2% | $164M+5.1% | $157M+4.0% | $153M+2.7% | $154M+3.4% | |
| Germany | $244M+6.6% | $240M+6.7% | $234M+6.4% | $229M+7.5% | $229M+10.1% | |
| Italy | $147M+12.2% | $138M+7.0% | $137M+6.2% | $133M+7.3% | $131M+6.5% | |
| Japan | $153M+7.7% | $150M+2.0% | $149M+1.4% | $148M0.0% | $142M-9.0% | |
| Mexico | $171M+6.9% | $158M-6.5% | $154M-10.5% | $152M-13.1% | $160M-4.2% | |
| Other developed markets | $677M+18.8% | $641M+13.7% | $610M+10.7% | $594M+12.1% | $570M+10.3% | |
| Other emerging markets | $956M+9.3% | $903M+4.4% | $886M+4.4% | $878M+7.6% | $875M+9.8% | |
| Spain | $152M+19.7% | $141M+8.5% | $134M+4.7% | $131M+6.5% | $127M+5.0% | |
| Total geographical area | $9.4B+2.5% | $9.33B+1.7% | $9.27B+2.1% | $9.26B+4.8% | $9.17B+6.0% | |
| United Kingdom | $326M+4.8% | $322M+2.5% | $317M+6.4% | $315M+6.4% | $311M+8.7% | |
| United States | $5B-1.8% | $5.1B+0.5% | $5.12B+1.8% | $5.14B+5.9% | $5.09B+8.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zoetis break its business down?
- Zoetis (ZTS) reports revenue by business across 2 parts — International and U.S.. Each is extracted from the segment footnotes and tracked over time.
- Where does Zoetis's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zoetis's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
